Table 2.
Baseline characteristics of different groups according to NFS status
| Variables | NFS levels | P | |||
|---|---|---|---|---|---|
| Low | Intermediate | High | |||
| Overall | < −1.455 | −1.455-0.676 | > 0.676 | ||
| n = 2008 | n = 798 | n = 1072 | n = 138 | ||
| Clinical data | |||||
| Age (years) | 55.5 ± 10.9 | 49.2 ± 10.1 | 58.7 ± 8.9 | 66.8 ± 8.7 | < 0.0001 |
| Male sex, n(%) | 1215 (60.6) | 506 (63.4) | 636 (59.3) | 73 (52.9) | 0.034 |
| BMI (kg/m2) | 25.7 ± 3.4 | 25 ± 3.2 | 26 ± 3.3 | 26.6 ± 4.1 | < 0.0001 |
| CAD, n(%) | 1179 (58.7) | 401 (50.3) | 681 (63.5) | 97 (70.3) | < 0.0001 |
| DM, n(%) | 471 (23.5) | 93 (11.7) | 327 (30.5) | 51 (37.0) | < 0.0001 |
| Hypertension, n(%) | 1229 (61.2) | 426 (53.4) | 703 (65.6) | 100 (72.5) | < 0.0001 |
| Family history of CAD, n(%) | 440 (21.9) | 195 (24.4) | 235 (21.9) | 10 (7.2) | < 0.0001 |
| Smoking, n(%) | 683 (34.0) | 303 (38.0) | 351 (32.7) | 29 (21.0) | < 0.0001 |
| Drinking, n(%) | 417 (20.8) | 185 (23.2) | 210 (19.6) | 22 (15.9) | 0.058 |
| SBP (mmHg) | 127.6 ± 18.5 | 125.2 ± 18 | 128.7 ± 18.7 | 132.7 ± 18.5 | < 0.0001 |
| DBP (mmHg) | 79.5 ± 11.2 | 79.9 ± 11.7 | 79.4 ± 10.9 | 77.8 ± 10.4 | 0.117 |
| Laboratory parameters | |||||
| Platelet (109/L) | 216.0 ± 53.6 | 247.36 ± 52.84 | 200.11 ± 40.91 | 157.41 ± 40.38 | < 0.0001 |
| ALT (IU/L) | 20 (14,28) | 22 (16,32) | 19 (14,27.75) | 14 (10,20) | < 0.0001 |
| AST (IU/L) | 18 (15,22) | 18 (15,22) | 18 (15,21) | 18.5 (15,24) | 0.375 |
| GGT (IU/L) | 25 (18,39) | 26.5 (18,43) | 24 (18,37) | 22 (16,33) | < 0.0001 |
| ALB (g/L) | 42.5 ± 4.3 | 44.0 ± 4.4 | 41.9 ± 3.8 | 39.0 ± 4.1 | < 0.0001 |
| TC (mmol/L) | 4.8 ± 1.01 | 4.90 ± 1.08 | 4.90 ± 0.95 | 4.60 ± 0.96 | 0.021 |
| TG (mmol/L) | 1.6 (1.15,2.31) | 1.61 (1.15,2.38) | 1.62 (1.18,2.31) | 1.42 (1.06,1.98) | 0.018 |
| HDL-C (mmol/L) | 1.11 ± 0.39 | 1.10 ± 0.43 | 1.12 ± 0.37 | 1.06 ± 0.30 | 0.109 |
| LDL-C (mmol/L) | 3.13 ± 0.91 | 3.14 ± 1.00 | 3.14 ± 0.85 | 2.98 ± 0.79 | 0.079 |
| Glucose (mmol/L) | 5.66 ± 1.96 | 5.00 ± 1.26 | 5.91 ± 2.36 | 5.73 ± 1.57 | < 0.0001 |
| HbA1C (%) | 6.05 ± 1.88 | 5.75 ± 2.02 | 6.24 ± 1.82 | 6.31 ± 0.92 | < 0.0001 |
| PCSK9(ng/mL) | 228.56 (190.57,272.29) | 224.72 (184.54,265.17) | 230.13 (193.44,275.58) | 244.28 (194.15,284.31) | 0.005 |
| Medication | |||||
| Antiplatelet drugs, n(%) | 595 (29.6) | 189 (23.7) | 361 (33.7) | 45 (32.6) | < 0.0001 |
| Antihypertensive drugs, n(%) | 694 (34.6) | 222 (27.8) | 414 (38.6) | 58 (42.0) | < 0.0001 |
NFS non-alcoholic fatty liver disease fibrosis score, PCSK9 proprotein convertase subtilisin/kexin type 9, BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transpeptidase, ALB albumin, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, HbA1C hemoglobin A1C, P < 0.05 suggests significant difference